These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24828352)

  • 1. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
    PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection.
    Silver ZA; Dickinson GM; Seaman MS; Desrosiers RC
    J Virol; 2019 May; 93(10):. PubMed ID: 30842322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.
    Blattner C; Lee JH; Sliepen K; Derking R; Falkowska E; de la Peña AT; Cupo A; Julien JP; van Gils M; Lee PS; Peng W; Paulson JC; Poignard P; Burton DR; Moore JP; Sanders RW; Wilson IA; Ward AB
    Immunity; 2014 May; 40(5):669-80. PubMed ID: 24768348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.
    Moyo T; Ereño-Orbea J; Jacob RA; Pavillet CE; Kariuki SM; Tangie EN; Julien JP; Dorfman JR
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29618644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.
    Louis JM; Aniana A; Lohith K; Sayer JM; Roche J; Bewley CA; Clore GM
    PLoS One; 2014; 9(8):e104683. PubMed ID: 25105806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
    Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
    Front Immunol; 2021; 12():670561. PubMed ID: 35003053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.
    Kumar S; Lin X; Ngo T; Shapero B; Sou C; Allen JD; Copps J; Zhang L; Ozorowski G; He L; Crispin M; Ward AB; Wilson IA; Zhu J
    mBio; 2021 Jun; 12(3):e0042921. PubMed ID: 34156262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
    Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
    PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.
    Zhou M; Meyer T; Koch S; Koch J; von Briesen H; Benito JM; Soriano V; Haberl A; Bickel M; Dübel S; Hust M; Dietrich U
    Eur J Immunol; 2013 Feb; 43(2):499-509. PubMed ID: 23180650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
    Heyndrickx L; Stewart-Jones G; Jansson M; Schuitemaker H; Bowles E; Buonaguro L; Grevstad B; Vinner L; Vereecken K; Parker J; Ramaswamy M; Biswas P; Vanham G; Scarlatti G; Fomsgaard A;
    PLoS One; 2013; 8(9):e74552. PubMed ID: 24023951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
    J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.